FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation Corrigendum in /10.3892/or.2020.7842

Xu,Ke; Zhang,Zhenhao; Pei,Hua; Wang,Huamin; Li,Liang; Xia,Qianfeng

doi:10.3892/or.2017.5459

FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation

Corrigendum in 10.3892/or.2020.7842

Authors:
- Ke Xu
- Zhenhao Zhang
- Hua Pei
- Huamin Wang
- Liang Li
- Qianfeng Xia
View Affiliations

Affiliations: Department of Immunology, School of Tropical and Laboratory Medicine, Hainan Medical University, Haikou, Hainan 571101, P.R. China, Medical Technology Institute of Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China, Key Laboratory of Tropical Biomedicine, and Faculty of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou, Hainan 571101, P.R. China
Published online on: February 16, 2017 https://doi.org/10.3892/or.2017.5459
Pages: 2391-2397

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM), the most common malignant brain tumor, is currently treated with temozolomide (TMZ), but GBM often exhibits resistance to TMZ. Although several mechanisms underlying GBM resistance to TMZ have been identified, these mechanisms are yet to fully explain how GBM gains resistance to TMZ. Our previous work has shown that FoxO3a, a member of the FoxO subfamily of transcription factors, promotes glioma cell proliferation and invasion. In this study, we sought to determine whether FoxO3a participates in TMZ resistance in GBM cells. Parental cell lines (also designated as sensitive cell lines) U87-MG and U251-MG, as well as the corresponding resistant cell lines U87-TR and U251-TR (generated by repeated TMZ treatments), were subjected to western blot analysis. Our results showed that the resistant cells (both U87-TRand U251-TR) exhibited higher levels of FoxO3a and β-catenin relative to their corresponding sensitive counterparts. Depletion of FoxO3a in the resistant cells enhanced the cytotoxic effect of TMZ. Further investigation showed that FoxO3a depletion did not affect the total protein level of β-catenin, but otherwise markedly reduced the nuclear β-catenin level. Taken together, these findings strongly support that FoxO3a renders GBM cells resistant to TMZ treatment, at least in part, through the regulation of β-catenin nuclear accumulation.

View Figures

View References

1	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
2	Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
3	Wang JY and Edelmann W: Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell. 9:417–418. 2006. View Article : Google Scholar : PubMed/NCBI
4	Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J and D'Atri S: DNA damage induced by temozolomide signals to both ATM and ATR: Role of the mismatch repair system. Mol Pharmacol. 66:478–491. 2004.PubMed/NCBI
5	Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP and Gilbert MR: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 26:4189–4199. 2008. View Article : Google Scholar : PubMed/NCBI
6	Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, et al: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 13:2038–2045. 2007. View Article : Google Scholar : PubMed/NCBI
7	Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL and Louis DN: MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 15:4622–4629. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sathornsumetee S and Rich JN: New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther. 6:1087–1104. 2006. View Article : Google Scholar : PubMed/NCBI
9	Peifer M, Rauskolb C, Williams M, Riggleman B and Wieschaus E: The segment polarity gene armadillo interacts with the wingless signaling pathway in both embryonic and adult pattern formation. Development. 111:1029–1043. 1991.PubMed/NCBI
10	Noordermeer J, Klingensmith J, Perrimon N and Nusse R: dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature. 367:80–83. 1994. View Article : Google Scholar : PubMed/NCBI
11	Peifer M, Berg S and Reynolds AB: A repeating amino acid motif shared by proteins with diverse cellular roles. Cell. 76:789–791. 1994. View Article : Google Scholar : PubMed/NCBI
12	Zhang ZQ, Chen HQ, Chen YH and Cheng XF: Significance of beta-catenin and Cyclin D1 express in glioma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 25:1010–1012. 2009.(In Chinese). PubMed/NCBI
13	Liu X, Wang L, Zhao S, Ji X, Luo Y and Ling F: β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells. Med Oncol. 28:608–614. 2011. View Article : Google Scholar : PubMed/NCBI
14	Liu C, Tu Y, Sun X, Jiang J, Jin X, Bo X, Li Z, Bian A, Wang X, Liu D, et al: Wnt/beta-Catenin pathway in human glioma: Expression pattern and clinical/prognostic correlations. Clin Exp Med. 11:105–112. 2011. View Article : Google Scholar : PubMed/NCBI
15	Rossi M, Magnoni L, Miracco C, Mori E, Tosi P, Pirtoli L, Tini P, Oliveri G, Cosci E and Bakker A: β-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther. 11:753–761. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pukkila MJ, Virtaniemi JA, Kumpulainen EJ, Pirinen RT, Johansson RT, Valtonen HJ, Juhola MT and Kosma VM: Nuclear beta catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol. 54:42–47. 2001. View Article : Google Scholar : PubMed/NCBI
17	Elzagheid A, Buhmeida A, Korkeila E, Collan Y, Syrjanen K and Pyrhonen S: Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol. 14:3866–3871. 2008. View Article : Google Scholar : PubMed/NCBI
18	Huang CL, Liu D, Ishikawa S, Nakashima T, Nakashima N, Yokomise H, Kadota K and Ueno M: Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer. 44:2680–2688. 2008. View Article : Google Scholar : PubMed/NCBI
19	Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
20	Lentsch AB, Kato A, Yoshidome H, McMasters KM and Edwards MJ: Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology. 32:169–173. 2000. View Article : Google Scholar : PubMed/NCBI
21	Sinnberg T, Menzel M, Ewerth D, Sauer B, Schwarz M, Schaller M, Garbe C and Schittek B: β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One. 6:e234292011. View Article : Google Scholar : PubMed/NCBI
22	Yu G, Wu F and Wang E: KLF8 promotes temozolomide resistance in glioma cells via β-catenin activation. Cell Physiol Biochem. 38:1596–1604. 2016. View Article : Google Scholar : PubMed/NCBI
23	Accili D and Arden KC: FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 117:421–426. 2004. View Article : Google Scholar : PubMed/NCBI
24	Calnan DR and Brunet A: The FoxO code. Oncogene. 27:2276–2288. 2008. View Article : Google Scholar : PubMed/NCBI
25	Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859. 2007. View Article : Google Scholar : PubMed/NCBI
26	Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, et al: Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One. 5:e122932010. View Article : Google Scholar : PubMed/NCBI
27	Storz P, Döppler H, Copland JA, Simpson KJ and Toker A: FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol Cell Biol. 29:4906–4917. 2009. View Article : Google Scholar : PubMed/NCBI
28	Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, et al: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 18:892–901. 2012. View Article : Google Scholar : PubMed/NCBI
29	Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
30	Lu J, Zhang F, Zhao D, Hong L, Min J, Zhang L, Li F, Yan Y, Li H, Ma Y, et al: ATRA-inhibited proliferation in glioma cells is associated with subcellular redistribution of beta-catenin via up-regulation of Axin. J Neurooncol. 87:271–277. 2008. View Article : Google Scholar : PubMed/NCBI
31	Shi ZD, Qian XM, Liu CY, Han L, Zhang KL, Chen LY, Zhang JX, Pu PY, Yuan XB and Kang CS: Chinese Glioma Cooperative Group (CGCG): Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation. CNS Neurosci Ther. 19:98–108. 2013. View Article : Google Scholar : PubMed/NCBI
32	Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM and Korswagen HC: Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science. 308:1181–1184. 2005. View Article : Google Scholar : PubMed/NCBI
33	Lan F, Pan Q, Yu H and Yue X: Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma. J Neurochem. 134:811–818. 2015. View Article : Google Scholar : PubMed/NCBI
34	Mrugala MM and Chamberlain MC: Mechanisms of disease: Temozolomide and glioblastoma - look to the future. Nat Clin Pract Oncol. 5:476–486. 2008. View Article : Google Scholar : PubMed/NCBI
35	Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, et al: Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest. 122:253–266. 2012. View Article : Google Scholar : PubMed/NCBI
36	Osuka S, Sampetrean O, Shimizu T, Saga I, Onishi N, Sugihara E, Okubo J, Fujita S, Takano S, Matsumura A, et al: IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells. 31:627–640. 2013. View Article : Google Scholar : PubMed/NCBI
37	Ryu CH, Yoon WS, Park KY, Kim SM, Lim JY, Woo JS, Jeong CH, Hou Y and Jeun SS: Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol. 2012:9874952012. View Article : Google Scholar : PubMed/NCBI
38	Bowman A and Nusse R: Location, location, location: FoxM1 mediates β-catenin nuclear translocation and promotes glioma tumorigenesis. Cancer Cell. 20:415–416. 2011. View Article : Google Scholar : PubMed/NCBI